<DOC>
	<DOCNO>NCT02303795</DOCNO>
	<brief_summary>RIvaroxaban Valvular heart diseasE atRial fibrillation trial ( RIVER trial ) .</brief_summary>
	<brief_title>RIvaroxaban Valvular Heart diseasE atRial Fibrillation Trial -RIVER Trial</brief_title>
	<detailed_description>A Phase 2 , Randomized , Open label , Non-Inferiority Clinical Trial Explore Safety Efficacy Rivaroxaban compare vitamin K antagonism Patients Atrial Fibrillation Bioprosthetic Mitral valves - RIVER .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Male female patient age &gt; 18 &lt; 80 year time inclusion 2 . Patients Persistent paroxysmal Atrial Fibrillation flutter bioprosthetic mitral valve . The patient must able give informed consent 1 . Cardiovascularrelated condition know presence cardiac thrombus tumor Active endocarditis Uncontrolled hypertension 2 . Hemorrhage riskrelated criterion Active internal bleeding History , condition associate , increase bleeding risk 3 . Concomitant condition therapy History previous thromboembolism high risk bleeding : Severe , disable stroke ( modify Rankin score 45 , inclusive ) within 3 month Acute thromboembolic event thrombosis ( venous/arterial ) within last 14 day prior randomization Acute MI within last 14 day prior randomization Treatment : Chronic aspirin therapy &gt; 100 mg daily dual antiplatelet therapy ; Intravenous antiplatelets ; Fibrinolytics ; Anticipated need longterm treatment nonsteroidal antiinflammatory drug ; Systemic treatment strong inhibitor cytochrome P450 3A4 , ketoconazole protease inhibitor ; Treatment strong inducer cytochrome P450 3A4 , rifampicin , phenytoin , phenobarbital , carbamazepine . Anemia Pregnancy breastfeed woman reproductive age use effective contraceptive method Calculated creatinine clearance bellow 30 mL/min Known significant liver disease alanine aminotransferase N3Ã— upper limit normal Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>bioprosthetic mitral valve</keyword>
	<keyword>valvular heart disease</keyword>
	<keyword>anticoagulant agent</keyword>
	<keyword>NOACs</keyword>
	<keyword>rivaroxaban</keyword>
	<keyword>warfarin</keyword>
</DOC>